about
Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemiasSplenectomy for people with thalassaemia major and intermediaDeferasirox for managing iron overload in people with thalassaemiaDeferasirox for managing iron overload in people with thalassaemiaSplenectomy for people with thalassaemia major or intermediaβ-thalassemia intermedia: a clinical perspectiveTreating iron overload in patients with non-transfusion-dependent thalassemiaThalassemia and spinal cord compression in pregnancy.Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.Liver iron content determination by magnetic resonance imaging.Beta-thalassaemia intermedia: evaluation of endocrine and bone complications.Paraspinal extramedullary hematopoiesis in patients with thalassemia intermediaClinical features and molecular analysis of Hb H disease in TaiwanPlasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemiaFrequency of cholelithiasis in patients with Beta-thalassemia intermedia with and without hydroxyurea.Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised conditionThalassaemia intermedia: an update.When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia.Hemoglobinopathies: clinical manifestations, diagnosis, and treatmentEndocrine and bone complications in β-thalassemia intermedia: current understanding and treatmentMinihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overloadSerum Ferritin Levels Correlation With Heart and Liver MRI and LIC in Patients With Transfusion-Dependent Thalassemia.Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients.Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias.Relationship Between Serum Hepcidin and Ferritin Levels in Patients With Thalassemia Major and Intermedia in Southern IranPrevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia.Hematological and biochemical status of Beta-thalassemia major patients in Bangladesh: A comparative analysis.Coronary atherosclerosis burden is not advanced in patients with β-thalassemia despite premature extracardiac atherosclerosis: a coronary artery calcium score and carotid intima-media thickness study.Non-transfusion-dependent thalassemias.Hemoglobin research and the origins of molecular medicine.Deferasirox: appraisal of safety and efficacy in long-term therapy.Paravertebral pseudotumor in patient with hereditary spherocytosisParaspinal and presacral extramedullary hematopoiesis: a rare manifestation of polycythemia vera.Hypothyroidism in β-Thalassemia Intermedia Patients with and without HydroxyureaExtramedullary hematopoiesis: A report of two cases.Extramedullary haematopoiesis correlates with genotype and absence of cardiac iron overload in polytransfused adults with thalassaemiaβ -thalassemia intermedia in Northern Iraq: a single center experienceHydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.Insight onto the pathophysiology and clinical complications of thalassemia intermedia.The hypercoagulable state in thalassemia intermedia.
P2860
Q24187646-075F75A0-8A1D-4464-A831-817560B25339Q24202998-EFF243C6-5D42-400D-87AF-2BE45F240CDAQ24203718-D66696BF-17F3-4DDD-9BF2-F7CE2A347C88Q24241753-C5A942DA-680D-49FE-89CC-8BAF880FCB18Q26471468-777AEEF8-4B25-4EE7-9E97-6A77E5308758Q26828512-2EDF0D8E-F48E-4672-915E-C0E4BA0E3ED0Q27009463-DE117518-422E-495E-A409-26001CDEE9B5Q30497418-19A8172E-9807-4512-987D-0101055ED0A3Q33436115-8494C396-CB0F-4CB8-A89B-4450870D6AEAQ33764777-B6A29271-173A-43BE-828B-3AA1738FA1BBQ33943025-C3E4D3AF-3D34-421E-9E4D-62B53FCABAC6Q33974681-BE79E3EF-F289-4A3A-8019-DD43DBE2D61FQ34176940-ECE77B0A-1A71-448A-A2BD-789CAB0F8FD3Q34188093-8EEDACA2-0D53-467E-8AC1-DDEF3943259DQ34197393-E9305E7D-D655-4AF9-8372-335C750470E8Q34324102-5824F5F4-DBD7-4D3E-974E-42FDAB3082B1Q34549431-7D734BB8-3D61-408B-B6B2-2358E2416ECEQ34999542-0459F0E1-A3FE-4191-AEEA-B044F7017A49Q35186540-CBD63E56-5646-4028-944B-9713E2DB018BQ35193628-EEA79140-F6A0-45F0-A4A9-E79324DECD9DQ35578602-FD057DC4-AAB1-47EB-AF56-584C7E3EB07DQ35644563-E79D3509-1552-4BD4-B05B-00869E80F16DQ35770785-649CADEC-18BA-4E79-BF3E-4CDE00B06FBDQ35788379-C59DFD39-F9FD-4355-9C84-02FC3360CE26Q35793024-1227087A-F007-490D-9A94-33C400A516ACQ36339553-F0AB01E3-DD7A-4C49-8475-B0205BDC2001Q36759582-A330EE0F-C7A8-4C66-B395-8D73A537A32DQ36863932-26F66955-650D-46C9-9C15-FA77E35C4C9DQ36892558-70A63C46-2654-419F-B6BC-38AEB843D388Q36969792-D8D538F9-A6CD-4CB5-B12C-CC34F418A64AQ37095523-31CC7845-81F8-4788-882B-C81DDA77397DQ37158007-C9385530-6A17-4B2C-B0FC-E32E0D1D7011Q37380274-5A5E88A8-1B15-4B7A-A812-35B0E4F08734Q37494096-ED613C04-335A-4048-9512-AD746CA83BEBQ37581639-DB808099-3182-4975-A263-2C9709D35053Q37602349-6612280E-68F4-4782-B8DB-A7E477ED89C4Q37639833-C7BA0FB8-77A5-4E10-9EAB-1DBD7115993AQ37642873-9BBB21B2-7197-45E1-953F-48D2BDBD8C75Q37650433-26EB996F-7BC7-4331-8737-034B74162920Q37650438-B4D7B78E-488F-449A-BA4E-365CB4A2B1E6
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Thalassemia intermedia: revisited.
@ast
Thalassemia intermedia: revisited.
@en
type
label
Thalassemia intermedia: revisited.
@ast
Thalassemia intermedia: revisited.
@en
prefLabel
Thalassemia intermedia: revisited.
@ast
Thalassemia intermedia: revisited.
@en
P1476
Thalassemia intermedia: revisited.
@en
P2093
Hussain Isma'eel
P356
10.1016/J.BCMD.2006.04.005
P577
2006-06-05T00:00:00Z